Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 6222.

https://doi.org/10.1182/blood-2024-205717

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Marie-Kristin Tilch, Christian Schmidt, Marek Trneny, Eva Gine, Olivier Hermine, Anke Ohler, Stephanie Herold, Marta Illenyi, Eva Hoster, Christiane Pott, Martin Dreyling, Georg Hess

Blood (2024) 144 (Supplement 1): 4422.3.

https://doi.org/10.1182/blood-2024-206931

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Blood (2023) 142 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2023-182896

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel J. Phillips, Matthew Matasar, Toby A. Eyre, Eva Gine, Audrey Filézac De L'Étang, Ben Byrne, Linda Lundberg, Alejandra Padovani, Christophe Boetsch, Alessia Bottos, Naseer Qayum

Blood (2023) 142 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2023-173946

Published: 2023

Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Blood (2022) 140 (Supplement 1): 10296–10299.

https://doi.org/10.1182/blood-2022-162638

Published: 2022

Journal Articles

Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model

Ferran Araujo-Ayala, Cèlia Dobaño-López, Juan G Valero, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Neus Serrat, Heribert Playa-Albinyana, Rubén Giménez, Elías Campo, Jean Michel Lagarde, Armando López-Guillermo, Eva Giné, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán

Blood (2022) 140 (Supplement 1): 1323–1324.

https://doi.org/10.1182/blood-2022-163381

Published: 2022

Journal Articles

Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes

Beatriz García-Torre, Marta Kulis, Mònica Romo, Anna Vidal, Stella Charalampopoulou, Vicente Chapaprieta, Martí Duran-Ferrer, Ferran Nadeu, Cristina López, Guillem Clot, Eva Giné, Armando Lopez-Guillermo, Sílvia Beà, Dolors Colomer, Elías Campo, José I. Martín-Subero

Blood (2022) 140 (Supplement 1): 1745–1746.

https://doi.org/10.1182/blood-2022-163085

Published: 2022

Journal Articles

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2022) 140 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2022-163018

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

Patricia Balsas, Luis Veloza, Guillem Clot, Marta Sureda-Gómez, Marta-Leonor Rodríguez, Christos Masaoutis, Gerard Frigola, Alba Navarro, Silvia Beà, Ferran Nadeu, Eva Giné, Armando López-Guillermo, Antonio Martínez, Inmaculada Ribera-Cortada, Pablo Engel, Leticia Quintanilla-Martínez, Wolfram Klapper, Elias Campo, Virginia Amador

Blood (2021) 138 (22): 2202–2215.

https://doi.org/10.1182/blood.2020010527

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Allison C. Rosenthal, Colleen Ramsower, Raphael Mwangi, Matthew J. Maurer, Diego Villa, Timothy J. McDonnell, Andrew L. Feldman, Thomas M. Habermann, Jonathon B. Cohen, Ryan S. Robetorye, Elías Campo, Eva Giné, James R. Cook, Brian T. Hill, Philipp Raess, German Ott, Alexander Reichart, David W. Scott, Lisa M. Rimsza

Blood (2021) 138 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2021-151275

Published: 2021

Journal Articles

Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140430

Published: 2020

Journal Articles

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Beatriz Rey Búa, Ana Jiménez Ubieto, MDPhD, Jose Javier Sanchez Blanco, Pau Abrisqueta, MD PhD, Antonio Gutierrez, Angel Ramirez Payer, Eva Giné, MD PhD, Izaskun Cebeiro, Sr., Maria Jose Terol, Fatima De la Cruz, MD, Rafael Andreu, María José Ramírez Sánchez, Adolfo de la Fuente, Ma Cruz Viguria, Maria Jesús Peñarrubia, Carlos Grande, Dolores Caballero, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-140786

Published: 2020

NARROW

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Utility of Baseline PET/CT As Surrogate of Molecular Features in Mantle Cell Lymphoma

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model

Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

SOX11, CD70, and T reg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma

Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab

Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Ibrutinib in Combination with R-Gemox-D in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Phase II Clinical Trial of the Geltamo Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only